Instrument Inactif

Communiqués Mateon Therapeutics Inc Nasdaq

Actions

US57667K1097

Recherche biotechnologique et médicale

Communiqués

03/08	Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th	AQ
23/07	Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle Technology Supporting the Ongoing Clinical Development of Sapu003	AQ
22/07	Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)	AQ
07/07	Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway	AQ
29/06	Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003	AQ
18/06	Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026	AQ
17/06	Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services	AQ
08/06	Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote	AQ
05/06	NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies	AQ
05/06	Oncotelic Therapeutics Inc. Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies	AQ
04/06	Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies	AQ
03/06	Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program	AQ
02/06	Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure	AQ
01/06	TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics	AQ
28/05	Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026	AQ
18/05	Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress	AQ
15/05	Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress	AQ
15/05	NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations	AQ
14/05	Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform	AQ
13/05	Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus	AQ
12/05	Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies	AQ
06/05	Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease	AQ
30/04	Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts	AQ
27/04	Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy	AQ
24/04	Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy	AQ